These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 7662995)

  • 21. Comparison of genomic DNA and cDNA for detection of residual disease after treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation.
    Zhang JG; Lin F; Chase A; Goldman JM; Cross NC
    Blood; 1996 Mar; 87(6):2588-93. PubMed ID: 8630427
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Distinct patterns of minimal residual disease associated with graft-versus-host disease after allogeneic bone marrow transplantation for chronic myelogenous leukemia.
    Pichert G; Roy DC; Gonin R; Alyea EP; Bélanger R; Gyger M; Perreault C; Bonny Y; Lerra I; Murray C
    J Clin Oncol; 1995 Jul; 13(7):1704-13. PubMed ID: 7602361
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detection of minimal residual disease in leukemia using polymerase chain reaction and restriction analysis.
    Wu N; Lu S; Zhu P; Liu L; Peng Y
    Chin Med J (Engl); 1997 Jan; 110(1):73-7. PubMed ID: 9594329
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [New findings in the diagnosis of minimal residual disease in acute leukemia with emphasis on flow cytometry].
    Vosková D; Váleková L; Kubisz P
    Vnitr Lek; 1997 May; 43(5):332-6. PubMed ID: 9601859
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Minimal residual disease in hematologic malignancies.
    San-Miguel JF; Bartram C; Campana D; Andreeff M
    Rev Invest Clin; 1994 Apr; Suppl():147-52. PubMed ID: 7886299
    [No Abstract]   [Full Text] [Related]  

  • 26. [Research on bone marrow cells in leukemias using microcalorimetric and autoradiographic methods].
    Dzhanimanov NB; Makhatadze IK; Chikhladze MSh; Monaselidze DR; Sheklashvili MSh
    Gematol Transfuziol; 1988 Mar; 33(3):58-60. PubMed ID: 3384303
    [No Abstract]   [Full Text] [Related]  

  • 27. Redefining treatment failure for pediatric acute leukemia in the era of minimal residual disease testing.
    Huynh V; Laetsch TW; Schore RJ; Gaynon P; O'Brien MM
    Pediatr Hematol Oncol; 2017; 34(6-7):395-408. PubMed ID: 29190162
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clonal evolution as the limiting factor in the detection of minimal residual disease by polymerase chain reaction in children in Brazil with acute lymphoid leukemia.
    Scrideli CA; Kashima S; Cipolloti R; Defavery R; Tone LG
    J Pediatr Hematol Oncol; 2002; 24(5):364-7. PubMed ID: 12142784
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Usefulness of quantitative assessment of the WT1 gene transcript as a marker for minimal residual disease detection.
    Cilloni D; Gottardi E; Fava M; Messa F; Carturan S; Busca A; Guerrasio A; Saglio G
    Blood; 2003 Jul; 102(2):773-4; author reply 774. PubMed ID: 12835231
    [No Abstract]   [Full Text] [Related]  

  • 30. Cutting edge technologies in the evaluation of bone marrow samples.
    Larson RS; McCurley TL
    Clin Lab Sci; 1996; 9(6):354-7. PubMed ID: 10165117
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Minimal residual disease in leukemia].
    Morishima Y
    Gan To Kagaku Ryoho; 1991 Sep; 18(12):2063-9. PubMed ID: 1888177
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Detection of the Mbcr/abl translocation using FISH in bone marrow samples from patients diagnosed with CML and ALL].
    Vargas MT; Fernández-Novoa MC; García-Creus MD; González-Ruano J
    Sangre (Barc); 1996 Oct; 41(5):399-400. PubMed ID: 9026927
    [No Abstract]   [Full Text] [Related]  

  • 33. Ficolled bone marrow is superior to bone marrow buffy coat for detection of minimal residual disease in multiple myeloma.
    Bai Y; Chim CS
    Hematology; 2019 Dec; 24(1):533-537. PubMed ID: 31280705
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Detection of minimal residual disease in acute and chronic leukemias.
    Radich J
    Curr Opin Hematol; 1996 Jul; 3(4):310-4. PubMed ID: 9372093
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Detection of CBF beta/MYH11 mRNA in bone marrow smears.
    Karlic H; Pavlova B; Koller E
    Leukemia; 1995 Mar; 9(3):520. PubMed ID: 7885052
    [No Abstract]   [Full Text] [Related]  

  • 36. False-positive residual disease assessment after bone marrow transplant in acute lymphoblastic leukemia.
    Langlands K; Goulden NJ; Steward CG; Potter MN; Cornish JM; Pamphilon DH; Oakhill A
    Blood; 1994 Aug; 84(4):1352-3. PubMed ID: 8049454
    [No Abstract]   [Full Text] [Related]  

  • 37. Detectable molecular residual disease at the beginning of maintenance therapy indicates poor outcome in children with T-cell acute lymphoblastic leukemia.
    Dibenedetto SP; Lo Nigro L; Mayer SP; Rovera G; Schilirò G
    Blood; 1997 Aug; 90(3):1226-32. PubMed ID: 9242556
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The clinical significance of residual disease in childhood acute lymphoblastic leukemia as detected by polymerase chain reaction amplification by antigen-receptor gene sequences.
    Roberts WM; Estrov Z; Kitchingman GR; Zipf TF
    Leuk Lymphoma; 1996 Jan; 20(3-4):181-97. PubMed ID: 8624456
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Correctly recognizing leukemic cells in bone marrow in infants: importance of good training in hematological morphology.
    Anand M; Kumar R; Ghara N; Thavaraj V
    Indian J Pathol Microbiol; 2005 Jul; 48(3):420-1. PubMed ID: 16761778
    [No Abstract]   [Full Text] [Related]  

  • 40. Minimal residual disease analysis by eight-color flow cytometry in relapsed childhood acute lymphoblastic leukemia.
    Karawajew L; Dworzak M; Ratei R; Rhein P; Gaipa G; Buldini B; Basso G; Hrusak O; Ludwig WD; Henze G; Seeger K; von Stackelberg A; Mejstrikova E; Eckert C
    Haematologica; 2015 Jul; 100(7):935-44. PubMed ID: 26001791
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.